<DOC>
	<DOC>NCT03022097</DOC>
	<brief_summary>This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).</brief_summary>
	<brief_title>Study to Patients With Stable COPD to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate (DUAKLIR)</brief_title>
	<detailed_description />
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1. Adult male or nonpregnant, nonlactating female patients aged ≥40 2. Patients with a diagnosis of COPD (GOLD guidelines, 2015) for a period of at least 6 months prior to Visit 1 (screening) 3. Patients with moderate to severe stable COPD (Stage II or Stage III, according to GOLD Guidelines 2015) at Visit 1: postbronchodilator FEV1 ≥30% and &lt; 80% and postbronchodilator FEV1/Forced vital capacity (FVC) &lt; 70% 4. Current or former smokers with a smoking history of ≥ 10 packyears 5. Patients able to perform repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1(screening ) 6. 6. Patients who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent 1. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff) or patients employed by or relatives of the employees of the site or sponsor. 2. Previous enrolment or randomisation in the present study 3. History or current diagnosis of asthma 4. Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the runin period 5. Patients hospitalized for COPD exacerbation (an emergency room visit for longer than 24 hours will be considered a hospitalization) within 3 months prior to screening and during the runin period 6. Clinically significant respiratory conditions other than COPD 7. Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to screening 8. Use of longterm oxygen therapy (≥15 hours/day) 9. Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers 10. Clinically significant cardiovascular conditions 11. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypoor hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension 12. Patients with QT corrected interval (QTc) using Fridericia formula (QTcF) (QTc=QT/ Duration in milliseconds between two R peaks of two consecutive QRS complexes (RR1/3) &gt;470 msec as indicated in the centralised reading report assessed at Screening (Visit 1) 13. Patients with clinically significant abnormalities in the clinical laboratory tests, ECG parameters (other than QTcF) or in the physical examination at Visit 1 (screening) 14. Patients with abnormal liver function tests defined as Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), or total bilirubin ≥ 2.5 times upper limit of normal ranges at screening 15. Patient with known noncontrolled history of infection with human immunodeficiency virus and/or active hepatitis 16. Patient with a history of hypersensitivity reaction to inhaled anticholinergic drugs, sympathomimetic amines, inhaled medication or any component thereof 17. Patient with known narrowangle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic nonstable prostatic hypertrophy 18. History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer 19. Any other serious or uncontrolled physical or mental dysfunction 20. Patients with a history (within 2 years prior to Visit 1 (screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment 21. Patients unlikely to be cooperative or cannot comply with the study procedures 22. Patients treated with any investigational drug within 30 days (or 6 halflives, whichever is longer) prior to screening 23. Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication 24. Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients 25. Any other conditions that, in the Investigator's opinion, might have indicated the patient to be unsuitable for the study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>